

JOIN US ON THE PATH TO POSSIBILITY

Lilly is dedicated to delivering life-changing medicines and support to people living with cancer. Please join us and our expert panel on the path to possibility as we pursue new medicines that bring new hope.

PERSONALISING AND OPTIMISING TREATMENT FOR METASTATIC NSCLC PATIENTS WITH EGFR AND OTHER CO-OCCURRING MUTATIONS



Sunday, 19 September, 2021 / 10:30–12:00 CEST (GMT +1)
Channel 4

10 minutes	Welcome and introduction	Chair – Martin Reck – Germany
20 minutes	Is a one-size-fits-all approach still appropriate for NSCLC with an EGFR mutation? Are all mutations equal?	Joachim Aerts – Netherlands
10 minutes	Scientific rationale for dual inhibition of VEGF and EGFR	Nobuyuki Takakura – Japan
15 minutes	Identifying the clinical and disease characteristics of the high-risk patient. What is the science telling us?	Federico Cappuzzo – Italy
15 minutes	Case study from the clinic	Chao-Hua Chiu – Taiwan
15 minutes	Panel discussion and Q&A	All panel
5 minutes	Symposium closing remarks	Chair – Martin Reck – Germany

Symposium Objectives

- Review the metastatic NSCLC EGFR mut +ve landscape and treatment outcomes of different mutations
- Understand the scientific rationale behind combining therapies and the impact on treatment outcomes
- Discuss TP53 co-mutations and other high-risk clinical and disease characteristics of patients with EGFR mut +ve metastatic NSCLC, including their negative impact on prognosis and response to therapy and their implications for optimising treatment decision-making and clinical outcomes